Company intelligence / Profile preview
Octapharma
Lachen, Schwyz, Switzerlandoctapharmausa.com ↗
- Ownership
- Private
- Employees
- ~11908
- Development stage
- Commercial
01
Overview
Octapharma has multiple commercialized products in hematology, immunotherapy, and critical care. Notable approvals include Nuwiq® for hemophilia A (EMA 2014, FDA 2015), panzyga® for primary immunodeficiency syndromes and immune thrombocytopenia (Canada/EU), fibryga® for congenital fibrinogen deficiency (EU/US/Canada), wilate with recent Orphan Drug exclusivity from the FDA in 2024, Balfaxar launched in 2024 for urgent reversal of acquired coagulation factor deficiency due to vitamin K antagonists. The company continues to expand indications through regulatory submissions.[2][5]
- Therapeutic areas
- HematologyImmunology
- Modalities
- Human plasma-derived proteinsRecombinant proteins (e.g., recombinant factor VIII)
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Octapharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Octapharma.